Edit count of the user (user_editcount) | 278 |
Name of the user account (user_name) | 'Sangsangaplaz' |
Age of the user account (user_age) | 25395806 |
Groups (including implicit) the user is in (user_groups) | [
0 => '*',
1 => 'user',
2 => 'autoconfirmed'
] |
Rights that the user has (user_rights) | [
0 => 'createaccount',
1 => 'read',
2 => 'edit',
3 => 'createtalk',
4 => 'writeapi',
5 => 'viewmyprivateinfo',
6 => 'editmyprivateinfo',
7 => 'editmyoptions',
8 => 'abusefilter-log-detail',
9 => 'urlshortener-create-url',
10 => 'centralauth-merge',
11 => 'abusefilter-view',
12 => 'abusefilter-log',
13 => 'vipsscaler-test',
14 => 'collectionsaveasuserpage',
15 => 'reupload-own',
16 => 'move-rootuserpages',
17 => 'createpage',
18 => 'minoredit',
19 => 'editmyusercss',
20 => 'editmyuserjson',
21 => 'editmyuserjs',
22 => 'sendemail',
23 => 'applychangetags',
24 => 'viewmywatchlist',
25 => 'editmywatchlist',
26 => 'spamblacklistlog',
27 => 'mwoauthmanagemygrants',
28 => 'reupload',
29 => 'upload',
30 => 'move',
31 => 'autoconfirmed',
32 => 'editsemiprotected',
33 => 'skipcaptcha',
34 => 'ipinfo',
35 => 'ipinfo-view-basic',
36 => 'transcode-reset',
37 => 'transcode-status',
38 => 'createpagemainns',
39 => 'movestable',
40 => 'autoreview'
] |
Whether the user is editing from mobile app (user_app) | false |
Whether or not a user is editing through the mobile interface (user_mobile) | false |
Page ID (page_id) | 7726945 |
Page namespace (page_namespace) | 0 |
Page title without namespace (page_title) | 'Perfluoro tert-butylcyclohexane' |
Full page title (page_prefixedtitle) | 'Perfluoro tert-butylcyclohexane' |
Edit protection level of the page (page_restrictions_edit) | [] |
Page age in seconds (page_age) | 537999885 |
Action (action) | 'edit' |
Edit summary/reason (summary) | 'removed advert template and copyedit' |
Old content model (old_content_model) | 'wikitext' |
New content model (new_content_model) | 'wikitext' |
Old page wikitext, before the edit (old_wikitext) | '{{Short description|Chemical compound}}
{{DISPLAYTITLE:Perfluoro ''tert''-butylcyclohexane}}
{{Drugbox
| drug_name = Perfluoro ''tert''-butylcyclohexane
| image = Perfluoro tert-butylcyclohexane.svg
| alt = The skeletal structure of an organic molecule
| tradename = Oxycyte
| CAS_number = 84808-64-0
| SMILES = C(C(F)(F)F)(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F
| StdInChI = 1S/C10F20/c11-2(1(8(22,23)24,9(25,26)27)10(28,29)30)3(12,13)5(16,17)7(20,21)6(18,19)4(2,14)15
| StdInChIKey = VLTXBOGHSBHSAC-UHFFFAOYSA-N
| PubChem = 15710945
| UNII = 3ZX1Z33VUU
| DrugBank = DB12477
| C=10 | F=20
}}
'''Perfluoro ''tert''-butylcyclohexane''' is a [[perfluorocarbon|perfluorinated chemical compound]] (or perfluorocarbon, PFC). It is a component of the empirical [[Blood substitute|therapeutic oxygen carrier]] called Oxycyte.<ref name="Haque_2016">{{cite journal | vauthors = Haque A, Scultetus AH, Arnaud F, Dickson LJ, Chun S, McNamee G, Auker CR, McCarron RM, Mahon RT | display-authors = 6 | title = The Emulsified PFC Oxycyte<sup>®</sup> Improved Oxygen Content and Lung Injury Score in a Swine Model of Oleic Acid Lung Injury (OALI) | journal = Lung | volume = 194 | issue = 6 | pages = 945–957 | date = December 2016 | pmid = 27704259 | doi = 10.1007/s00408-016-9941-9 }}</ref>
==Chemical properties==
Perfluoro ''tert''-butyl-cyclo-hexane is a [[Saturated and unsaturated compounds|saturated]] [[alicyclic]] perfluorocarbon with the molecular formula C<sub>10</sub>F<sub>20</sub>.<ref>{{cite book | vauthors = Shaw R, Richard T | chapter = Chapter 27 – Rational Development of Oxyfluor |title=Blood Substitutes| veditors = Winslow RM |publisher=Academic Press|year= 2006 |page= 303 |isbn=978-0127597607 | chapter-url=https://books.google.com/books?id=kkbJ5D2n4koC&dq=C10F20&pg=PA303}}</ref><ref>{{cite patent | country = US | number = 2013096190 | title = Perfluorocarbon gel formulations | assign1 = Oxygen Biotherapeutics, Inc. | pubdate = 18 April 2013 | inventor = Huvard G, Kiral R, Quitaro M, Thompson DP, Grossman A, Clauson G, Sandhu G | postscript = . }}</ref> [[Fluorocarbon]]s are known for their strong gas-dissolving properties which, when used with [[oxygen]], serve a dual role of healing the tissue as well as [[Oxygen sensor|imaging]]. It fits the imaging role promisingly due to its biocompatibility and half-life. A similar compound, [[perfluorobutane|perfluoro-butane]], is already used for ultrasound imaging.<ref>{{cite journal | vauthors = Darçot E, Colotti R, Brennan D, Deuchar GA, Santosh C, van Heeswijk RB | title = A characterization of ABL-101 as a potential tracer for clinical fluorine-19 MRI | journal = NMR in Biomedicine | volume = 33 | issue = 1 | pages = e4212 | date = January 2020 | pmid = 31724252 | doi = 10.1002/nbm.4212 | s2cid = 208018877 }}</ref><ref>{{Cite web |date=January 10, 2007 |title=Ultrasound Contrast Agent Sonazoid® for Injection Released for Sale |url=https://www.daiichisankyo.com/files/news/pressrelease/pdf/005564/news2007_01_10_69_en.pdf | work = Daiichi Sankyo Company, Ltd. }}</ref> Healing [[decompression sickness]] with oxygen has a similar mechanism of action to healing brain [[anemia]], and so Oxycyte can be used for this.<ref>{{cite journal | vauthors = Mahon RT, Cronin WA, Bodo M, Tirumala S, Regis DP, Auker CR | title = Cardiovascular parameters in a mixed-sex swine study of severe decompression sickness treated with the emulsified perfluorocarbon Oxycyte | journal = Journal of Applied Physiology | volume = 118 | issue = 1 | pages = 71–79 | date = January 2015 | pmid = 25342702 | doi = 10.1152/japplphysiol.00727.2014 }}</ref><ref>{{cite journal | vauthors = Mahon RT, Auker CR, Bradley SG, Mendelson A, Hall AA | title = The emulsified perfluorocarbon Oxycyte improves spinal cord injury in a swine model of decompression sickness | journal = Spinal Cord | volume = 51 | issue = 3 | pages = 188–192 | date = March 2013 | pmid = 23165506 | doi = 10.1038/sc.2012.135 | s2cid = 11694901 | doi-access = free }}</ref>
==Oxycyte==
{{Advert|section|date=September 2017}}
Oxycyte is a perfluorocarbon (PFC) product composed of submicron particles of perfluoro(t-butylcyclohexane) in a 60% w/v concentration with an egg phospholipid emulsifier.<ref name="Haque_2016" />
Oxycyte was invented by [[Leland Clark]] and developed by Tenex Therapeutics, formerly Oxygen Biotherapeutics, Inc. and Synthetic Blood International.<ref>{{Cite web|url=http://www.tenaxthera.com/pipeline/oxycyte/|title=Oxycyte {{!}} Tenax Therapeutics|website=www.tenaxthera.com|language=en-US|access-date=2017-01-24}}</ref> It is designed to enhance oxygen delivery to damaged tissues. Through a collaborative agreement, Oxycyte (under the development code name of ABL-101) was being developed by Aurum Biosciences Ltd, with an initial indication in acute ischemic stroke.<ref>{{Cite web |url=http://www.aurumbiosciences.com/ |title=Aurum Biosciences |website=www.aurumbiosciences.com |language=en-GB |access-date=2017-01-24}}</ref>
Tenex claims that Oxycyte can carry oxygen with up to 5 times the efficiency of [[hemoglobin]] when used as an intravenous emulsion, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.<ref>{{cite web | url = http://oxybiomed.com | archive-url = https://web.archive.org/web/20100402093937/http://www.oxybiomed.com/ | archive-date = 2 April 2010 | title = Oxygen Biotherapeutics, Inc. }}</ref> However, because Oxycyte is a PFC and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products. There have been no adverse events in company clinical trials related to Oxycyte. Tenex believed Oxycyte has a very favorable risk-benefit profile for its potential indications.
Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to an all time high. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>
Around September 2004, Oxycyte completed Phase I trials with few mild side effects.<ref>{{Cite web |title=Synthetic Blood International Announces Preliminary Analysis of Oxycyte Phase I Study Results - O-STA |url=https://o-sta.si/en/1819/synthetic-blood-international-announces-preliminary-analysis-of-oxycyte-phase-i-study-results |access-date=2022-09-04 |website=o-sta.si}}</ref> Clinical interest in Oxycyte began to grow during this period, culminating in 2013.<ref name="PubMed">{{Cite web |title=Oxycyte - Search Results |url=https://pubmed.ncbi.nlm.nih.gov/?term=Oxycyte&sort=date |access-date=2022-09-04 | work = PubMed | publisher = U.S. National Library of Medicine |language=en}}</ref>
Aurum Biosciences received a Wellcome Trust HICF funding to conduct a Phase I clinical trial with Oxycyte in stroke patients. This study investigated both therapeutic potential and its ability to enhance the diagnostic potential of an MRI in suspected stroke patients.<ref>{{Cite web|url=https://wellcome.org/what-we-do/directories/health-innovation-challenge-fund-projects-funded|title=Health Innovation Challenge Fund: projects we've funded | location = UK | work = Wellcome |archive-url= https://web.archive.org/web/20210124080954/https://wellcome.org/what-we-do/directories/health-innovation-challenge-fund-projects-funded |language=en|access-date=2017-01-24|archive-date=2021-01-24 }}</ref><ref>{{Cite web|url=http://www.aurumbiosciences.com/technology-and-products/|title=Technology and Products | work = Aurum Biosciences |language=en-GB|access-date=2017-01-24}}</ref><ref>{{cite patent|title=Method of imaging metabolic function|gdate = 9 September 2015 |inventor=Santosh C, Brennan D | assign1 = The Greater Glasgow Health Board |country=US|number=9144392 | postscript = . }}</ref>
In September 2014, Oxygen Biotherapeutics announced the discontinuation of a Phase IIB trial for its Oxycyte drug candidate, citing "difficulties enrolling patients".<ref>{{cite web |url=https://www.businesswire.com/news/home/20140911006403/en/Oxygen-Biotherapeutics-Announces-Halt-Oxycyte-Phase-IIb |title=Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial |website=businesswire.com |date=September 11, 2014}}</ref> Clinical interest in Oxycyte has since tapered off.<ref name="PubMed" />
Oxycyte has been linked to potentially dangerous variations in blood viscosity.<ref>{{cite journal | vauthors = Arnaud F, Sanders K, Sieckmann D, Moon-Massat P | title = In vitro alteration of hematological parameters and blood viscosity by the perfluorocarbon: Oxycyte | journal = International Journal of Hematology | volume = 103 | issue = 5 | pages = 584–591 | date = May 2016 | pmid = 26886450 | doi = 10.1007/s12185-016-1955-9 | s2cid = 19287551 }}</ref>
== References ==
{{Reflist}}
== External links ==
* [https://go.drugbank.com/drugs/DB12477 Drugbank DB12477: Perfluoro tert-butylcyclohexane]
[[Category:Blood substitutes]]
[[Category:Fluorocarbons]]' |
New page wikitext, after the edit (new_wikitext) | '{{Short description|Chemical compound}}
{{DISPLAYTITLE:Perfluoro ''tert''-butylcyclohexane}}
{{Drugbox
| drug_name = Perfluoro ''tert''-butylcyclohexane
| image = Perfluoro tert-butylcyclohexane.svg
| alt = The skeletal structure of an organic molecule
| tradename = Oxycyte
| CAS_number = 84808-64-0
| SMILES = C(C(F)(F)F)(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F
| StdInChI = 1S/C10F20/c11-2(1(8(22,23)24,9(25,26)27)10(28,29)30)3(12,13)5(16,17)7(20,21)6(18,19)4(2,14)15
| StdInChIKey = VLTXBOGHSBHSAC-UHFFFAOYSA-N
| PubChem = 15710945
| UNII = 3ZX1Z33VUU
| DrugBank = DB12477
| C=10 | F=20
}}
'''Perfluoro ''tert''-butylcyclohexane''' is a [[perfluorocarbon|perfluorinated chemical compound]] (or perfluorocarbon, PFC). It is a component of the empirical [[Blood substitute|therapeutic oxygen carrier]] called Oxycyte.<ref name="Haque_2016">{{cite journal | vauthors = Haque A, Scultetus AH, Arnaud F, Dickson LJ, Chun S, McNamee G, Auker CR, McCarron RM, Mahon RT | display-authors = 6 | title = The Emulsified PFC Oxycyte<sup>®</sup> Improved Oxygen Content and Lung Injury Score in a Swine Model of Oleic Acid Lung Injury (OALI) | journal = Lung | volume = 194 | issue = 6 | pages = 945–957 | date = December 2016 | pmid = 27704259 | doi = 10.1007/s00408-016-9941-9 }}</ref>
==Chemical properties==
Perfluoro ''tert''-butyl-cyclo-hexane is a [[Saturated and unsaturated compounds|saturated]] [[alicyclic]] perfluorocarbon with the molecular formula C<sub>10</sub>F<sub>20</sub>.<ref>{{cite book | vauthors = Shaw R, Richard T | chapter = Chapter 27 – Rational Development of Oxyfluor |title=Blood Substitutes| veditors = Winslow RM |publisher=Academic Press|year= 2006 |page= 303 |isbn=978-0127597607 | chapter-url=https://books.google.com/books?id=kkbJ5D2n4koC&dq=C10F20&pg=PA303}}</ref><ref>{{cite patent | country = US | number = 2013096190 | title = Perfluorocarbon gel formulations | assign1 = Oxygen Biotherapeutics, Inc. | pubdate = 18 April 2013 | inventor = Huvard G, Kiral R, Quitaro M, Thompson DP, Grossman A, Clauson G, Sandhu G | postscript = . }}</ref> [[Fluorocarbon]]s are known for their strong gas-dissolving properties which, when used with [[oxygen]], serve a dual role of healing the tissue as well as [[Oxygen sensor|imaging]]. It fits the imaging role promisingly due to its biocompatibility and half-life. A similar compound, [[perfluorobutane|perfluoro-butane]], is already used for ultrasound imaging.<ref>{{cite journal | vauthors = Darçot E, Colotti R, Brennan D, Deuchar GA, Santosh C, van Heeswijk RB | title = A characterization of ABL-101 as a potential tracer for clinical fluorine-19 MRI | journal = NMR in Biomedicine | volume = 33 | issue = 1 | pages = e4212 | date = January 2020 | pmid = 31724252 | doi = 10.1002/nbm.4212 | s2cid = 208018877 }}</ref><ref>{{Cite web |date=January 10, 2007 |title=Ultrasound Contrast Agent Sonazoid® for Injection Released for Sale |url=https://www.daiichisankyo.com/files/news/pressrelease/pdf/005564/news2007_01_10_69_en.pdf | work = Daiichi Sankyo Company, Ltd. }}</ref> Healing [[decompression sickness]] with oxygen has a similar mechanism of action to healing brain [[anemia]], and so Oxycyte can be used for this.<ref>{{cite journal | vauthors = Mahon RT, Cronin WA, Bodo M, Tirumala S, Regis DP, Auker CR | title = Cardiovascular parameters in a mixed-sex swine study of severe decompression sickness treated with the emulsified perfluorocarbon Oxycyte | journal = Journal of Applied Physiology | volume = 118 | issue = 1 | pages = 71–79 | date = January 2015 | pmid = 25342702 | doi = 10.1152/japplphysiol.00727.2014 }}</ref><ref>{{cite journal | vauthors = Mahon RT, Auker CR, Bradley SG, Mendelson A, Hall AA | title = The emulsified perfluorocarbon Oxycyte improves spinal cord injury in a swine model of decompression sickness | journal = Spinal Cord | volume = 51 | issue = 3 | pages = 188–192 | date = March 2013 | pmid = 23165506 | doi = 10.1038/sc.2012.135 | s2cid = 11694901 | doi-access = free }}</ref>
==Oxycyte==
Oxycyte is a perfluorocarbon (PFC) product composed of submicron particles of perfluoro(t-butylcyclohexane) in a 60% w/v concentration with an egg phospholipid emulsifier.<ref name="Haque_2016" />
Oxycyte was invented by [[Leland Clark]] and developed by Tenex Therapeutics, formerly Oxygen Biotherapeutics, Inc. and Synthetic Blood International.<ref>{{Cite web|url=http://www.tenaxthera.com/pipeline/oxycyte/|title=Oxycyte {{!}} Tenax Therapeutics|website=www.tenaxthera.com|language=en-US|access-date=2017-01-24}}</ref> It is designed to enhance oxygen delivery to damaged tissues. Through a collaborative agreement, Oxycyte (under the development code name of ABL-101) was being developed by Aurum Biosciences Ltd, with an initial indication in acute ischemic stroke.<ref>{{Cite web |url=http://www.aurumbiosciences.com/ |title=Aurum Biosciences |website=www.aurumbiosciences.com |language=en-GB |access-date=2017-01-24}}</ref>
Tenex claims that Oxycyte can carry oxygen with up to 5 times the efficiency of [[hemoglobin]] when used as an intravenous emulsion, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.<ref>{{cite web | url = http://oxybiomed.com | archive-url = https://web.archive.org/web/20100402093937/http://www.oxybiomed.com/ | archive-date = 2 April 2010 | title = Oxygen Biotherapeutics, Inc. }}</ref> However, because Oxycyte is a PFC and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products. There have been no adverse events in company clinical trials related to Oxycyte. Tenex believed Oxycyte has a very favorable risk-benefit profile for its potential indications.
Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to its peak. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>
Around September 2004, Oxycyte completed Phase I trials with few mild side effects.<ref>{{Cite web |title=Synthetic Blood International Announces Preliminary Analysis of Oxycyte Phase I Study Results - O-STA |url=https://o-sta.si/en/1819/synthetic-blood-international-announces-preliminary-analysis-of-oxycyte-phase-i-study-results |access-date=2022-09-04 |website=o-sta.si}}</ref> Clinical interest in Oxycyte began to grow during this period, culminating in 2013.<ref name="PubMed">{{Cite web |title=Oxycyte - Search Results |url=https://pubmed.ncbi.nlm.nih.gov/?term=Oxycyte&sort=date |access-date=2022-09-04 | work = PubMed | publisher = U.S. National Library of Medicine |language=en}}</ref>
Aurum Biosciences received a Wellcome Trust HICF funding to conduct a Phase I clinical trial with Oxycyte in stroke patients. This study investigated both therapeutic potential and its ability to enhance the diagnostic potential of an MRI in suspected stroke patients.<ref>{{Cite web|url=https://wellcome.org/what-we-do/directories/health-innovation-challenge-fund-projects-funded|title=Health Innovation Challenge Fund: projects we've funded | location = UK | work = Wellcome |archive-url= https://web.archive.org/web/20210124080954/https://wellcome.org/what-we-do/directories/health-innovation-challenge-fund-projects-funded |language=en|access-date=2017-01-24|archive-date=2021-01-24 }}</ref><ref>{{Cite web|url=http://www.aurumbiosciences.com/technology-and-products/|title=Technology and Products | work = Aurum Biosciences |language=en-GB|access-date=2017-01-24}}</ref><ref>{{cite patent|title=Method of imaging metabolic function|gdate = 9 September 2015 |inventor=Santosh C, Brennan D | assign1 = The Greater Glasgow Health Board |country=US|number=9144392 | postscript = . }}</ref>
In September 2014, Oxygen Biotherapeutics announced the discontinuation of a Phase IIB trial for its Oxycyte drug candidate, citing "difficulties enrolling patients".<ref>{{cite web |url=https://www.businesswire.com/news/home/20140911006403/en/Oxygen-Biotherapeutics-Announces-Halt-Oxycyte-Phase-IIb |title=Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial |website=businesswire.com |date=September 11, 2014}}</ref> Clinical interest in Oxycyte has since tapered off.<ref name="PubMed" />
Oxycyte has been linked to potentially dangerous variations in blood viscosity.<ref>{{cite journal | vauthors = Arnaud F, Sanders K, Sieckmann D, Moon-Massat P | title = In vitro alteration of hematological parameters and blood viscosity by the perfluorocarbon: Oxycyte | journal = International Journal of Hematology | volume = 103 | issue = 5 | pages = 584–591 | date = May 2016 | pmid = 26886450 | doi = 10.1007/s12185-016-1955-9 | s2cid = 19287551 }}</ref>
== References ==
{{Reflist}}
== External links ==
* [https://go.drugbank.com/drugs/DB12477 Drugbank DB12477: Perfluoro tert-butylcyclohexane]
[[Category:Blood substitutes]]
[[Category:Fluorocarbons]]' |
Unified diff of changes made by edit (edit_diff) | '@@ -22,5 +22,4 @@
==Oxycyte==
-{{Advert|section|date=September 2017}}
Oxycyte is a perfluorocarbon (PFC) product composed of submicron particles of perfluoro(t-butylcyclohexane) in a 60% w/v concentration with an egg phospholipid emulsifier.<ref name="Haque_2016" />
@@ -29,5 +28,5 @@
Tenex claims that Oxycyte can carry oxygen with up to 5 times the efficiency of [[hemoglobin]] when used as an intravenous emulsion, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.<ref>{{cite web | url = http://oxybiomed.com | archive-url = https://web.archive.org/web/20100402093937/http://www.oxybiomed.com/ | archive-date = 2 April 2010 | title = Oxygen Biotherapeutics, Inc. }}</ref> However, because Oxycyte is a PFC and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products. There have been no adverse events in company clinical trials related to Oxycyte. Tenex believed Oxycyte has a very favorable risk-benefit profile for its potential indications.
-Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to an all time high. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>
+Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to its peak. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>
Around September 2004, Oxycyte completed Phase I trials with few mild side effects.<ref>{{Cite web |title=Synthetic Blood International Announces Preliminary Analysis of Oxycyte Phase I Study Results - O-STA |url=https://o-sta.si/en/1819/synthetic-blood-international-announces-preliminary-analysis-of-oxycyte-phase-i-study-results |access-date=2022-09-04 |website=o-sta.si}}</ref> Clinical interest in Oxycyte began to grow during this period, culminating in 2013.<ref name="PubMed">{{Cite web |title=Oxycyte - Search Results |url=https://pubmed.ncbi.nlm.nih.gov/?term=Oxycyte&sort=date |access-date=2022-09-04 | work = PubMed | publisher = U.S. National Library of Medicine |language=en}}</ref>
' |
New page size (new_size) | 9579 |
Old page size (old_size) | 9626 |
Size change in edit (edit_delta) | -47 |
Lines added in edit (added_lines) | [
0 => 'Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to its peak. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>'
] |
Lines removed in edit (removed_lines) | [
0 => '{{Advert|section|date=September 2017}}',
1 => 'Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases. These claims raised Tenex's stock price to an all time high. Since then, the stock price has plummeted with no signs of recovery.<ref>{{Cite news |date=December 15, 2006 |title=Man Made Life Saver 50x Better Than Blood |url=https://www.trendhunter.com/trends/oxycyte-man-made-life-saver-50x-better-than-blood}}</ref><ref>{{Cite web |title=Tenax Therapeutics Stock Price Today (NASDAQ: TENX) Quote, Market Cap, Chart {{!}} WallStreetZen |url=https://www.wallstreetzen.com/stocks/us/nasdaq/tenx |access-date=2022-09-04 |website=www.wallstreetzen.com}}</ref>'
] |
Whether or not the change was made through a Tor exit node (tor_exit_node) | false |
Unix timestamp of change (timestamp) | '1700400278' |
